In:
Liver Transplantation, Ovid Technologies (Wolters Kluwer Health), Vol. 21, No. 6 ( 2015-06), p. 718-737
Abstract:
The liver plays a major role in many inherited and acquired genetic disorders. It is also the site for the treatment of certain inborn errors of metabolism that do not directly cause injury to the liver. The advancement of nucleic acid–based therapies for liver maladies has been severely limited because of the myriad untoward side effects and methodological limitations. To address these issues, research efforts in recent years have been intensified toward the development of targeted gene approaches using novel genetic tools, such as zinc‐finger nucleases, transcription activator‐like effector nucleases, and clustered regularly interspaced short palindromic repeats as well as various nonviral vectors such as Sleeping Beauty transposons, PiggyBac transposons, and PhiC31 integrase. Although each of these methods uses a distinct mechanism of gene modification, all of them are dependent on the efficient delivery of DNA and RNA molecules into the cell. This review provides an overview of current and emerging therapeutic strategies for liver‐targeted gene therapy and gene repair. Liver Transpl 21:718‐737, 2015 . © 2015 AASLD.
Type of Medium:
Online Resource
ISSN:
1527-6465
,
1527-6473
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2015
detail.hit.zdb_id:
2002186-0
